Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.

• Abstract: PURPOSE: This study was to investigate the effect of capecitabine on recurrent tumor and metastasis after curative resection of liver cancer, xenograft of a highly metastatic human hepatocellular carcinoma (HCC) tumor (LCI-D20), with special reference to the expression of platelet-derived endothelial cell growth factor (PD-ECGF). EXPERIMENTAL DESIGN: LCI-D20 and LCI-D35 (a low metastatic human HCC model) liver tumors were orthotopically implanted in 96 nude mice and divided into a treatment group (24 LCI-D20 mice and 24 LCI-D35 mice) and a prevention group (48 LCI-D20 mice). In the prevention group, curative resection of liver tumors was done 10 days after the orthotopic implantation of LCI-D20 tumor. Arabic gum (control), 5-fluorouracil (5-FU), and capecitabine were administrated respectively to all of the 96 mice. RESULTS: In the treatment group, tumor volume was 468 +/- 138, 442 +/- 81, and 240 +/- 119 mm3 (P<0.01) in the control, 5-FU, and capecitabine subgroups, respectively, in LCI-D20 mice, whereas it was 168 +/- 35, 164 +/- 23, and 144 +/- 21 mm3 (P>0.05), respectively, in LCI-D35 mice. In the prevention group, incidence of liver recurrence in the control, 5-FU, and capecitabine subgroups was 100, 100, and 50%; lung metastasis being 100, 100, and 17%; and life span being 31 +/- 5, 37 +/- 5, and 77 +/- 19 days, respectively. PD-ECGF was highly expressed in HCC and its metastatic tissues in LCI-D20 mice and hardly expressed in HCC tissues in LCI-D35 mice. CONCLUSIONS: Capecitabine inhibits tumor growth and metastatic recurrence after resection of HCC in highly metastatic nude mice model. The effect of capecitabine may be attributed to the high expression of PD-ECGF in tumors.
• Authors: Jian Zhou, Zhao-You Tang, Jia Fan, Zhi-Quan Wu, Yuan Ji, Yong-Sheng Xiao, Ying-Hong Shi, Xiao-Ming Li, Qi-Man Sun, Yin-Kun Liu, Sheng-Long Ye (Affiliation: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.)
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 9 Issue 16 Pt 1 Pg. 6030-7 (Dec 1 2003) ISSN: 1078-0432 [Print] United States
• PMID: 14676129 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antimetabolites, Antineoplastic
• capecitabine
• Fluorouracil
• Deoxycytidine
• Thymidine Phosphorylase

Topics

• Animals
• Antimetabolites, Antineoplastic (therapeutic use)
• Carcinoma, Hepatocellular (metabolism, prevention & control, surgery)
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Fluorouracil (analogs & derivatives)
• Humans
• Liver Neoplasms, Experimental (metabolism, prevention & control, surgery)
• Male
• Mice
• Mice, Inbred BALB C
• Mice, Nude
• Neoplasm Metastasis (drug therapy)
• Neoplasm Recurrence, Local (drug therapy)
• Postoperative Care
• Thymidine Phosphorylase (metabolism)
• Transplantation, Heterologous